Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Whales are coming in.
Sandler Capitol Funds to increase shareholding in BioLife Solutions, Inc. (unquote). As I said earlier...The whales re coming in.
All I can find is this:
https://finance.yahoo.com/news/top-ranked-momentum-stocks-buy-133701425.html
Make that $19.00+
Good news today...Whales will be buying into this gem...Now we go up.
16.23 booom!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Chart says we're pass $15.00 already. Charts don't lie.
Wish I had gotten in earlier. This company is really doing well.
BLFS breaking 15.00 boooyah!!! 16.23 next!!
Another blow out Q.
Full Year 2018 Revenue Guidance Increased
BOTHELL, Wash., July 2, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today reported preliminary revenue for the three months ended June 30, 2018 and increased its revenue guidance for 2018.
Second quarter 2018 preliminary revenue from sales of BioLife's biopreservation media products reached a record $5.2 million. This represents a 103% increase from the second quarter of 2017 and a 36% increase from the first quarter of 2018.
BioLife CEO Mike Rice commented, "Strong product demand during the second quarter from our cell and gene therapy customers in the regenerative medicine market segment resulted in more than 100% revenue growth over the prior-year period. Given our performance for the first half of 2018, increased adoption of our products in cell therapy clinical trials, and our outlook on product demand for the remainder of the year, we are significantly increasing our revenue guidance for the full year 2018."
Management estimates that BioLife's proprietary biopreservation media products have been used in nearly 300 customer clinical applications, including dozens of CAR T-cell and other T cell immunotherapies targeting blood cancers and solid tumors as well as other cell types targeting debilitating diseases and disorders.
Roderick de Greef, Chief Financial Officer, remarked, "Based primarily on additional warrant exercises during the period, we ended the second quarter with more than $14 million in cash, up from $7 million at March 31, 2018."
Management is raising its revenue guidance for the full year 2018 as follows:
Biopreservation media revenue is now expected to be in a range of $18.5 million to $20 million, representing growth of approximately 68% to 82% over 2017. This is an increase from the Company's prior revenue guidance issued in April 2018 of a range of $14.5 million to $15.5 million.
Management is affirming the remainder of its financial guidance for 2018 as follows:
Gross margin is expected to be between 63% and 65%, up from 61% for 2017.
Operating expenses are expected to range from $9.0 million to $9.5 million, compared with $7.8 million for 2017.
Full year GAAP operating profit with proportional increases in adjusted EBITDA and cash flow from operations.
https://finance.yahoo.com/news/biolife-solutions-reports-second-quarter-120000661.html
BLFS nice shake...you aint gettin my shares
Nice call. Have you run out of predictions?
They just keeping growing a nice clip. Priced at disaster when they lost the large contract biz for a couple million a year. Replaced it with much better margin biz.
A few trials that get approved using their cryostor and now shippers each year and they will keep on growing.
BLFS here's the 12.80 ring a ding ding!!! link back!!
koolmc: Do you have a reason to be negative about this stock?
Or are you just wary of the current price?
The greatest BIO i have been in. Pitch perfect chart...see ya at 12.80 if we can break this minor cloud resistance!!
lol you are fos
I'm not seeing any gaps that haven't been filled.
It has been on a tear because they reported their first quarter of positive earnings, got themselves added to the Russell Microcap Index, and had very good forward looking statements while trying to be conservative about their projections. All this following many consecutive quarters of earnings growth.
This company has a bright future.
Welcome to the Russell Microcap Index.
https://finance.yahoo.com/news/biolife-solutions-join-russell-microcap-164900209.html
"Russell US Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell US Indexes. Russell US Indexes are part of FTSE Russell, a leading global index provider."
Is there a chance that Trump's "Right to Try" bill that just passed is positively influencing BLFS?
Will this open more opportunity for BLFS's customers to require more product as the usual path to using their solutions will not be necessary for these patients?
Yes. Institutional buying?
Looks like the beast enjoyed the long weekend.
Missed this Zacks review from a week ago. Looks like they were right.
https://finance.yahoo.com/news/biolife-solutions-blfs-shares-march-140502581.html
I love the way management is trying to remain conservative with their projections.
The potential is enormous.
This transcript of the earnings conference call is a good read:
https://finance.yahoo.com/news/edited-transcript-blfs-earnings-conference-203630534.html
I think you're right. This looks like a break out.
Mike Rice, BioLife President & CEO, commented, "We are off to a very strong start in 2018, with record revenue in Q1, 36 new direct customers gained, and operating profitability for the first time in the Company's history. BioLife is well positioned as a sole-source supplier of proprietary biopreservation media reagents to the biopharmaceutical industry, which are critical enabling components to therapies that are transforming the way leading disorders and causes of death are treated. We expect continued strong results throughout 2018, given increasing regenerative medicine investments and M&A activity and clinical development progress by our cell therapy customers that continues to drive strong demand for our products."
https://finance.yahoo.com/news/biolife-solutions-announces-first-quarter-200500025.html
So it went up to that space between our predictions and, in typical BLFS fashion prior to the earnings report, backed off. It will probably back off some more after the release tomorrow.
Still holding. Still waiting for more of their customers to get their processes approved so that the demand picks up.
BLFS monster...get ready for 11.00!!!
And here we are at $8.39. Let's see what happens.
I see resistance from 2013 at $8.40. Also from connecting the high in July 2016 through the peak in October 2017.
https://yhoo.it/2I1cFl0
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
859
|
Created
|
04/25/07
|
Type
|
Free
|
Moderators |
http://www.biolifesolutions.com/
Company Information:
BioLife Solutions, Inc.
3303 Monte Villa Parkway
Suite 310
Bothell, WA 98021
USA
1.866.4BIOLIFE (N. America) (1.866.424.6543)
1.425.402.1400
Phone: 607.687.4487
Fax: 607.687.6683
CIK
0000834365
Whether cryopreserving your cells for long-term storage or just using temporary cold storage, BioLife Solutions has ready-to-use, fully defined products that will protect your cell or tissue samples as they undergo the rigors of preservation.
Our HypoThermosol¨ and CryoStor™ preservation lines are:
Our quality assurance includes sterility and endotoxin testing as well as bioassay testing to ensure lot-to-lot consistent performance. A partial list of the cell types our products have been tested with includes the following:
Tested Cell Types | |
Liver Cells (Hepatocytes & C3A) | Cardiomyocytes |
Stem Cells | Hybridomas |
PBMC | Pancreatic Islets |
Cord Blood | Skeletal Muscle Cells (SKMC) |
T-Cells | Smooth Muscle Cells (CASMC) |
Lymphocytes | PBSC |
Coronary Artery Endothelial Cells (CAEC) | Chondrocytes |
Cancer Cells (PC3, LNCaP) | CHO |
Skeletal Myoblasts | C2C12 |
Neuronal Cells | Ocular (BCE, HCE) |
Keratinocytes (A431) | Engineered tissue |
Renal Cells (RPTEC, MDCK) | Organ / Tissue |
Fibroblasts (NHDF, 3T3) | Vascular Tissue |
Transfected Cells | Hair Follicle |
HEK | Dendritic Cells |
These factors along with our patented formula make our HypoThermosol¨ and CryoStor™ lines unique in the area of preservation solutions. The CryoStor™ and HypoThermosol¨ family of products has quickly become the technology of choice in a broad range of applications.
Recent News:
http://www.biolifesolutions.com/press/press_releases.htm
Filings:
Transfer Agent:
American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038
Investor Relations:
Len Hall Matt Clawson
BioLife Solutions BioLife Solutions
(949) 474-4300 (949) 474-4300
len@allencaron.com matt@allencaron.com
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |